MICROSPONGE BASED CANDESARTAN CILEXETIL LOADED PULSINCAP FOR ACHIEVING CHRONOMODULATED DRUG DELIVERY

Candesartan Cilexetil (CC) traditional dosage form has poor bioavailability and quick first pass metabolism, which leads to rapid elimination of the drug from the system and reduced plasma drug concentration during early morning heart attack incidence. The primary purpose of the Candesartan Cilexetil chronotherapeutic formulation is to optimally release the medicine in greater amounts in the early morning hours (when it is most needed) and in lower amounts at night (when it is least needed). Because systolic and diastolic blood pressures increase fast in the early morning by at least 15 to 25 mmHg and peak late in the day, Candesartan Cilexetil was successfully developed as microsponges to enhance its solubility and bioavailability and delivered as the pulsatile release (Pulsincap dosage form) for delivering the drug after the lag time of 5-6 h for the chronomodulated release of the drug. Microsponges and Pulsincap were subjected to various formulation parameters like FTIR, DSC, encapsulation efficiency, SEM, in-vitro dissolution and kinetic study. F9 formulation was selected as best formulation as it offered a required lag time of 5 h and achieved a cumulative percent drug release of 95.87% over a period of 24 h. The drug release of F9 follows zero order kinetics. From the outcomes, it is evident that the solubility and bioavailability can be improved and the drug can be delivered as pulsatile delivery for an effective treatment of the morning spike of hypertension.